Novartis India Ltd. engages in developing and marketing transformative treatments for people in areas of medical need. The company is headquartered in Mumbai, Maharashtra and currently employs 81 full-time employees. The firm focuses on over three divisions, including pharmaceuticals, eye care and generic medicines. In India, its pharmaceutical business is focused on bone and pain, calcium portfolio, gynecology and neurosciences, and the generics business is focused on gynecology, anti-tuberculosis (TB) and anti-infectives. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolism, immunology and dermatology, ophthalmology, neuroscience and respiratory. The company develops gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The company is developing a chimeric antigen receptor (CAR)-T platform for various investigational CAR-T therapies in its pipeline. The firm has presence in various locations in India, including Delhi, Bengaluru, Kolkata, Chennai and Lucknow.
Loading chart…
This company hasn't held an earnings call in the last six months, so there's no recent commentary from management. Our deep dives are built on what management actually said, so we haven't prepared one.